# Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus

> **NCT00739635** · PHASE3 · COMPLETED · sponsor: **Merz Pharmaceuticals GmbH** · enrollment: 411 (actual)

## Conditions studied

- Subjective Tinnitus

## Interventions

- **DRUG:** Neramexane mesylate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00739635
- **Lead sponsor:** Merz Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00739635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00739635, "Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00739635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*